Asset Details
Do you wish to reserve the book?
SOX2 drives esophageal squamous carcinoma by reprogramming lipid metabolism and histone acetylation landscape
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
SOX2 drives esophageal squamous carcinoma by reprogramming lipid metabolism and histone acetylation landscape
Do you wish to request the book?
SOX2 drives esophageal squamous carcinoma by reprogramming lipid metabolism and histone acetylation landscape
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
SOX2 drives esophageal squamous carcinoma by reprogramming lipid metabolism and histone acetylation landscape
2025
Overview
SOX2 is a potent oncodriver for various squamous cancers, but the underlying mechanism is largely unknown. Here we uncover a role of SOX2 in promoting global histone acetylation in esophageal squamous cancer cells (ESCCs). Mechanistic studies reveal that SOX2 promotes global histone acetylation in an AKT-independent manner, and does so by promoting histone acetylation at both SOX2 binding and non-SOX2 binding sites, and accounts for the formation of about half of the super-enhancers. Combined metabolic and transcriptional analyses reveal two mechanisms by which SOX2 enhances global histone acetylation: promoting the expression of multiple histone acetyltransferases and reducing acetyl-CoA consuming fatty acid synthesis in part by repressing the expression of ACSL5. Finally, SOX2 expression correlates negatively with ACSL5 and positively with histone acetylation in clinical esophageal squamous tumors. Altogether, our study uncovers a role of SOX2 in reprogramming lipid metabolism and driving histone hyperacetylation and super-enhancer function, providing mechanistic insights of SOX2 acting as a potent oncodriver.
SOX2 is known to be oncogenic in squamous cell carcinomas. Here, the authors demonstrate that SOX2 promotes global histone acetylation and reprograms lipid metabolism in esophageal squamous cell carcinoma cells.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 13/51
/ 38/109
/ 38/15
/ 38/39
/ 38/88
/ 38/89
/ 59
/ 64
/ Acetate-CoA Ligase - genetics
/ Acetate-CoA Ligase - metabolism
/ Cancer
/ Carcinoma, Squamous Cell - genetics
/ Carcinoma, Squamous Cell - metabolism
/ Carcinoma, Squamous Cell - pathology
/ Coenzyme A Ligases - genetics
/ Coenzyme A Ligases - metabolism
/ Esophageal Neoplasms - genetics
/ Esophageal Neoplasms - metabolism
/ Esophageal Neoplasms - pathology
/ Esophageal Squamous Cell Carcinoma - genetics
/ Esophageal Squamous Cell Carcinoma - metabolism
/ Gene Expression Regulation, Neoplastic
/ Histone Acetyltransferases - genetics
/ Histone Acetyltransferases - metabolism
/ Histones
/ Humanities and Social Sciences
/ Humans
/ Kinases
/ Lipids
/ Proteins
/ Science
/ SOXB1 Transcription Factors - genetics
